2022
Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial
Ghazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAcute heart failureHeart failurePragmatic trialElectronic health recordsSubstantial health care costsBest practice advisoryReduced ejection fractionUsual care armHealth recordsTime of dischargeEvidence-based careHealth care costsClinical decision support systemAHF patientsCare armEligible patientsHF hospitalizationInpatient initiationCardiovascular deathMedication classesEjection fractionMedical therapyPrimary outcomePractice advisoryElectronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial
Ghazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, Martin M, O'Connor KD, Simonov M, Huang J, Olufade T, McDermott J, Dhar R, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, Ahmad T. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial. Journal Of The American College Of Cardiology 2022, 79: 2203-2213. PMID: 35385798, DOI: 10.1016/j.jacc.2022.03.338.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyUsual careEjection fractionHeart failureMedical therapyPrimary outcomeCluster-randomized comparative effectiveness trialSodium-glucose cotransporter 2 inhibitorsElectronic health record alertsAldosterone system inhibitorsReduced ejection fractionUsual care armCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsVentricular ejection fractionComparative effectiveness trialNumber of patientsKnowledge of guidelinesLow-cost interventionCare armDays postrandomizationEligible patientsGDMT useFailure therapyPatient characteristicsThirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries
Reinhardt SW, Clark KAA, Xin X, Parzynski CS, Riello R, Sarocco P, Ahmad T, Desai NR. Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation Cardiovascular Quality And Outcomes 2022, 15: e008069. PMID: 35861780, DOI: 10.1161/circoutcomes.121.008069.Peer-Reviewed Original ResearchConceptsHypertensive heart diseaseIndex hospitalizationMedicare beneficiariesPost-acute care spendingService administrative claims dataMedicare Bundled PaymentsHeart failure admissionsHeart failure hospitalizationPrimary discharge diagnosisChronic kidney diseaseAdministrative claims dataCare spendingPostacute care spendingSkilled nursing facilitiesCare Improvement ProgramDrivers of costDiastolic HFHF careHF hospitalizationSystolic HFFailure hospitalizationDischarge diagnosisKidney diseaseObservation staysPostacute careRationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2024
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis
Bansal K, Majmundar V, Young G, Riello R, Faridi K, Ahmad T, Desai N. Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis. JACC Heart Failure 2024, 12: 1791-1793. PMID: 39115517, DOI: 10.1016/j.jchf.2024.07.002.Peer-Reviewed Original ResearchPragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial
Shah N, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, Riello Iii R, Faridi K, Ahmad T, Wilson F, Desai N. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010335. PMID: 38634282, DOI: 10.1161/circoutcomes.123.010335.Peer-Reviewed Original ResearchElectronic health recordsElectronic health record alertsHigh-risk atherosclerotic cardiovascular diseaseLipid lowering therapyAtherosclerotic cardiovascular diseasePragmatic trialCardiovascular diseaseProportion of patientsYale New Haven HealthLDL-CSecondary outcomesPrimary outcomeInternal medicine cliniciansEHR alertUsual careHealth recordsProvider levelCluster-randomizedLDL-C managementLDL-C levelsAdverse cardiovascular eventsRandomized clinical trialsTreatment of hyperlipidemiaCliniciansCardiovascular eventsELECTRONIC ALERTS TO IMPROVE MINERALOCORTICOID RECEPTOR ANTAGONIST USE AND HYPERKALEMIA MANAGEMENT IN AMBULATORY PATIENTS WITH HEART FAILURE: A CLUSTER RANDOMIZED TRIAL
Clark K, Victoria-Castro A, Ghazi, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. ELECTRONIC ALERTS TO IMPROVE MINERALOCORTICOID RECEPTOR ANTAGONIST USE AND HYPERKALEMIA MANAGEMENT IN AMBULATORY PATIENTS WITH HEART FAILURE: A CLUSTER RANDOMIZED TRIAL. Journal Of The American College Of Cardiology 2024, 83: 2395. DOI: 10.1016/s0735-1097(24)04385-7.Peer-Reviewed Original Research
2023
Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use
Clark K, Victoria-Castro A, Ghazi L, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC Heart Failure 2023, 12: 322-332. PMID: 37943221, DOI: 10.1016/j.jchf.2023.08.025.Peer-Reviewed Original ResearchBest practice alertMineralocorticoid receptor antagonistsNovel potassium bindersPotassium bindersEligible patientsUsual careEjection fractionSerum potassiumHistory of hyperkalemiaIncidence of hyperkalemiaStrong guideline recommendationsHeart failure hospitalizationReduced ejection fractionLaboratory test valuesPopulation health outcomesHyperkalemia treatmentMRA prescriptionAntagonist useFailure hospitalizationPatient characteristicsSecondary outcomesHeart failurePrimary outcomeGuideline recommendationsOutpatient visitsElectronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial
Ghazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.Peer-Reviewed Original ResearchGuideline-directed medical therapyAcute heart failureMineralocorticoid receptor antagonistsHeart failureElectronic health recordsGDMT prescriptionPrimary outcomeEnzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitorsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorElectronic health record alertsEvidence-based regimenProviders of patientsReduced ejection fractionCotransporter 2 inhibitorsRelevant patient characteristicsTime of dischargePre-specified criteriaAHF hospitalizationEligible patientsInpatient initiationPatient characteristicsEjection fractionHospitalized patientsMedian age
2021
Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF)
Ghazi L, Desai NR, Simonov M, Yamamoto Y, O'Connor KD, Riello RJ, Huang J, Olufade T, McDermott J, Inzucchi SE, Velazquez EJ, Wilson FP, Ahmad T. Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). American Heart Journal 2021, 244: 107-115. PMID: 34808104, DOI: 10.1016/j.ahj.2021.11.010.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyBest practice alertLeft ventricular ejection fractionHeart failureUsual careMedical therapyPragmatic trialElectronic health recordsEjection fractionCluster-randomized pragmatic trialLarge integrated healthcare systemDays post randomizationAppropriate medical therapyHeart Failure TrialReduced ejection fractionUsual care groupCommon chronic illnessGlomerular filtration rateVentricular ejection fractionRecent blood pressureIntegrated healthcare systemUse of guidelinesLow-cost interventionCreatinine levelsReal-world practiceA Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
Ahmad T, Riello RJ, Inzucchi SE. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review 2021, 16: e11. PMID: 33897837, PMCID: PMC8054345, DOI: 10.15420/ecr.2020.01.r1.Peer-Reviewed Original ResearchSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsType 2 diabetesCardiovascular diseaseHigh-risk type 2 diabetes patientsGlucagon-like peptide-1 receptor agonistsMajor adverse cardiovascular eventsSpecific glucose-lowering agentsPeptide-1 receptor agonistsRecent clinical trial dataType 2 diabetes patientsAdverse cardiovascular eventsHeart failure hospitalizationGlucose-lowering agentsClinical trial dataAnti-diabetes drugsCardiovascular eventsCardiovascular outcomesDiabetes medicationsFailure hospitalizationCardiovascular riskHeart failurePharmacological treatmentSafe prescribingDiabetes patientsEffect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure
Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.Peer-Reviewed Original ResearchConceptsEnd-stage heart failureReduced ejection fractionHealth-related qualityPatient-reported health statusEffect of inotropesHeart failureHealth status domainsEjection fractionHealth statusFunctional statusPositive inotropesStatus domainsAvailable clinical trial dataMorbidity/mortalityPopulation of patientsPatient-centered outcomesHealth status outcomesClinical trial dataFunctional capacity changesQuantity of lifeWeb of ScienceInotrope therapyInotrope useCalcium sensitizerSurvival benefitNINETY-DAY EPISODE OF CARE SPENDING FOLLOWING HEART FAILURE HOSPITALIZATION AMONG MEDICARE BENEFICIARIES
Reinhardt S, Clark K, Xin X, Parzynski C, Riello R, Sarocco P, Ahmad T, Desai N. NINETY-DAY EPISODE OF CARE SPENDING FOLLOWING HEART FAILURE HOSPITALIZATION AMONG MEDICARE BENEFICIARIES. Journal Of The American College Of Cardiology 2021, 77: 786. DOI: 10.1016/s0735-1097(21)02145-8.Peer-Reviewed Original Research
2025
Medicare Coverage and Patient Out-of-Pocket Costs for Mavacamten
Bansal K, Chien C, Masri A, Riello R, Ahmad T, Desai N, Dani S. Medicare Coverage and Patient Out-of-Pocket Costs for Mavacamten. Circulation Cardiovascular Quality And Outcomes 2025, 18: e011331. PMID: 39817331, DOI: 10.1161/circoutcomes.124.011331.Peer-Reviewed Original Research
2017
075 Urine Galectin-3 Levels Identify High Risk Renal Dysfunction in Patients with Heart Failure
Ahmad T, Rao V, Chunara Z, Mahoney D, Jackson K, Hodson D, Tarleton C, Thomas D, Chen M, Jacoby D, Riello R, Testani J. 075 Urine Galectin-3 Levels Identify High Risk Renal Dysfunction in Patients with Heart Failure. Journal Of Cardiac Failure 2017, 23: s32. DOI: 10.1016/j.cardfail.2017.07.084.Peer-Reviewed Original Research055 Torsemide Does Not Have Clinically Relevant Anti-Aldosterone Effects in Human Heart Failure
Mahoney D, Rao V, Jackson K, Chunara Z, Hodson D, Tarleton C, Thomas D, Chen M, Jacoby D, Riello R, Ahmad T, Testani J. 055 Torsemide Does Not Have Clinically Relevant Anti-Aldosterone Effects in Human Heart Failure. Journal Of Cardiac Failure 2017, 23: s25. DOI: 10.1016/j.cardfail.2017.07.063.Peer-Reviewed Original Research054 Inflammation and Cardio-Renal Interactions in Heart Failure: A Potential Role for Interleukin-6
Jackson K, Rao V, Hanberg J, Mahoney D, Chunara Z, Thomas D, Hodson D, Tarleton C, Chen M, Jacoby D, Riello R, Ahmad T, Testani J. 054 Inflammation and Cardio-Renal Interactions in Heart Failure: A Potential Role for Interleukin-6. Journal Of Cardiac Failure 2017, 23: s25. DOI: 10.1016/j.cardfail.2017.07.062.Peer-Reviewed Original Research010 Urine Sodium Content is Highly Variable in Hospitalized Acute Heart Failure Patients: Lasix Urine is Not Necessarily “Half-Normal Saline”
Chunara Z, Jackson K, Rao V, Mahoney D, Thomas D, Tarleton C, Hodson D, Chen M, Jacoby D, Riello R, Ahmad T, Testani J. 010 Urine Sodium Content is Highly Variable in Hospitalized Acute Heart Failure Patients: Lasix Urine is Not Necessarily “Half-Normal Saline”. Journal Of Cardiac Failure 2017, 23: s7. DOI: 10.1016/j.cardfail.2017.07.013.Peer-Reviewed Original Research007 Acute Tubular Injury is Not a Major Mechanism for Worsening Renal Function in Patients Treated for Acute Heart Failure
Hodson D, Jackson K, Ahmad T, Rao V, Mahoney D, Tarleton C, Chunara Z, Thomas D, Chen M, Jacoby D, Riello R, Testani J. 007 Acute Tubular Injury is Not a Major Mechanism for Worsening Renal Function in Patients Treated for Acute Heart Failure. Journal Of Cardiac Failure 2017, 23: s6. DOI: 10.1016/j.cardfail.2017.07.010.Peer-Reviewed Original ResearchDRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME ASSOCIATED EOSINOPHILIC MYOCARDITIS TREATED WITH TOFACITINIB AN ORAL JANUS (JAK) KINASE INHIBITOR
Azari B, Chowdhury M, Riello R, Sthalekar N, King B, Ahmad T. DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS) SYNDROME ASSOCIATED EOSINOPHILIC MYOCARDITIS TREATED WITH TOFACITINIB AN ORAL JANUS (JAK) KINASE INHIBITOR. Journal Of The American College Of Cardiology 2017, 69: 2351. DOI: 10.1016/s0735-1097(17)35740-6.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply